论文部分内容阅读
治疗性抗体正在成为新药开发的新亮点,这些都得益于它可特异的识别靶位。众所周知,目前常用的单克隆抗体多为鼠源,在临床应用方面受到多种限制。与之相比,由于兔的免疫系统自身的特点,兔源单克隆抗体(RabMAbs)具有更高的亲和力和特异性,能识别更多的抗原表位。RabMAbs已在生命科学研究领域中广泛应用,其作为生物标志物已应用到临床诊断和新药研发之中。随着谱系引导的人源化改变(mutational lineage-guided humanization)理论提出和进一步深入研究,使得RabMAbs的人源化不但相对容易还可以对抗原互补决定区与框架区进行人源化。因此,有理由相信治疗性RabMAbs的开发和应用前景更为广阔。文中就RabMAbs的特点、优势、诊断和治疗性RabMAbs的发展状况做一综述。
Therapeutic antibodies are emerging as a new bright spot in the development of new drugs thanks to their specific target recognition. As we all know, the commonly used monoclonal antibodies are mostly murine, subject to a variety of restrictions in clinical applications. In contrast, rabbit-derived mAbs (RabMAbs) have higher affinity and specificity and recognize more epitopes because of the rabbit’s own immune system. RabMAbs is widely used in life sciences and has been used as a biomarker in clinical diagnostics and drug discovery. With the introduction and further research of the theory of lineage-guided humanization, it is not only relatively easy to humanize RabMAbs, but also humanized the complementarity-determining regions and the framework regions. Therefore, there is reason to believe that the development and application of therapeutic RabMAbs will have a broader prospect. The article reviews the features, advantages, diagnoses and therapeutic status of RabMAbs.